The malaria parasite metabolizes haemoglobin and detoxifies the resulting haem by polymerizing it to form haemozoin (malaria pigment). A polymer identical to haemozoin, -haematin, can be obtained in vitro from haematin at acidic pH. Quinoline-containing antimalarials (e.g. chloroquine) inhibit the formation of either polymer. Haem polymerization is an essential and unique pharmacological target. To identify molecules with haem polymerization inhibitory activity (HPIA) and quantify their potency, we developed a simple, inexpensive, quantitative in-vitro spectrophotometric microassay of haem polymerization. The assay uses 96-well U-bottomed polystyrene microplates and requires 24 h and a microplate reader. The relative amounts of polymerized and unpolymerized haematin are determined, based on solubility in DMSO, by measuring absorbance at 405 nm in the presence of test compounds as compared with untreated controls. The final product (a solid precipitate of polymerized haematin) was validated using infrared spectroscopy and the assay proved reproducible; in this assay, activity could be partly predicted based on the compound's chemical structure. Both water-soluble and water-insoluble compounds can be quantified by this method. Although the throughput of this assay is lower than that of radiometric methods, the assay is easier to set up and cheaper, and avoids the problems related to radioactive waste disposal.
Introduction
Malaria continues to be a major public health problem worldwide; the deadly Plasmodium falciparum is becoming increasingly resistant to available drugs and the number of drugs under development is dwindling. 1 Antimalarial drugs may be broadly classified in two groups: lysosomotropic quinoline-containing drugs and antimetabolites. The former include quinine and quinidine, the 4-aminoquinolines, chloroquine and amodiaquine, and the quinolino-methanol mefloquine. Quinoline-containing drugs have been the mainstay of antimalarial treatment for decades and are still widely used. Although the clinical use of quinolines is hampered by various degrees of parasite resistance, 2,3 there is still interest in drugs that share the same biochemical target, inasmuch as it is essential and unique to the parasite, and resistance to quinoline drugs occurs via different mechanisms. 4, 5 The main target for quinoline antimalarials is haem polymerization, a process whereby intraerythrocytic-stage malaria parasites detoxify haem in the digestive vacuole.
Haem is a by-product of haemoglobin digestion, and is used by the parasite as a source of most of its essential amino acids; 6 it is potentially toxic to biological membranes and parasite enzymes 7, 8 and is thus sequestered in the form of an insoluble crystalline polymer, haemozoin (or malaria pigment). 6 Haem can be polymerized in vitro, in the absence of proteins, from a solution of haematin at 70°C or 37°C at acidic pH. 9, 10 The resulting polymer, -haematin, appears to retain the chemical, spectroscopic and biological properties of the native pigment. 9, 11, 12 Quinoline antimalarials have been shown to inhibit both synthetic and native polymerization. 10, 13, 14 Chloroquine appears to act by forming quinoline-haem complexes which terminate haemozoin chain extension. 15, 16 The ability of drugs to inhibit haem polymerization is directly related to their antimalarial potency. 13 A radiolabelled haem incorporation assay 16 is currently used for testing compounds. However, it is expensive and uses trophozoite lysates and radiolabelled haemin, and many laboratories are not equipped to conduct this assay 55 A microtitre-based method for measuring the haem polymerization inhibitory activity (HPIA) of antimalarial drugs routinely. The search for new antimalarials would benefit from a rapid, reproducible method for identifying molecules that interfere with haem polymerization. We report here on a simple and inexpensive in-vitro microassay of haem polymerization which allows identification of molecules with haem polymerization inhibitory activity (HPIA) and quantification of their HPIA relative to that of standard quinoline antimalarials. The assay is intended either for primary screening of molecules (which will then be tested in the whole parasite in-vitro system using P. falciparum) or for studying the mechanism of action of compounds with known antimalarial activity. 
Materials and methods

Assay for haem polymerization
One hundred microlitres of a 4 mM solution of haematin, previously dissolved in 0.1 M NaOH, were distributed in 96-well U-bottomed microplates (0.4 mol/well) (Costar 3799). Fifty microlitres of different doses of antimalarial drugs at a drug:haem ratio of between 1:1 to 8:1 were added to triplicate test wells. Either 50 L of water or 50 L of the solvent used to solubilize the drugs were added to control wells. Haematin polymerization was initiated by adding 0.8 mmol of acetic acid (50 L) at a final pH of 3 and the suspension was incubated at 37°C for 24 h to allow complete polymerization. Plates were then centrifuged at 3300g for 15 min and the soluble fraction of unprecipitated material collected (fraction I). The remaining pellet was resuspended with 200 L of DMSO to remove unreacted haematin. Plates were then centrifuged again at 3300g for 15 min. The DMSO-soluble fraction (fraction II) was collected and the pellet, consisting of a pure precipitate of -haematin, was dissolved in 0.1 M NaOH (fraction III) for spectroscopic quantification. A 150 L aliquot of each fraction was transferred on to a new plate and serial four-fold dilutions in 0.1 M NaOH were performed. The amount of haematin was determined by measuring the absorbance at 405 nm using a microtitre plate reader (Molecular Devices Co., Manlo Park, CA, USA). A standard curve for haematin dissolved in 0.1 M NaOH was used to calculate the amount of porphyrin present in each fraction. The data are expressed as the molar equivalents of test compounds relative to haematin required to inhibit haem polymerization by 50% (IC 50 ).
Infrared spectroscopy
Infrared spectra were obtained using KBr pellets prepared from dried samples of fractions II and III, using a Jasco Fourier-transformed infrared (FT-IR) spectrometer. 17 
Statistical analysis
All tests were performed at least three times in triplicate and the results were analysed by one-way analysis of variance (ANOVA).
Results and discussion
Haematin polymerization in acidic conditions to form -haematin was achieved using 96-well U-bottomed polystyrene microplates in a final volume of 200 L. Microtitre plates offer several advantages over larger vessels for screening compounds because (i) drugs and samples are easily assayed in triplicate or quadruplicate; (ii) automated multichannel pipettors, plate shakers and washers as well as table-top centrifuges can be used for dispensing samples and recovering the supernatants; (iii) the amount of precipitate can be monitored spectrophotometrically using microtitre plate readers; and (iv) assay throughput is increased.
A preliminary series of experiments with a range of concentrations established that the optimal concentration of haematin in the starting solution was 0.2-0.8 mol/well: larger amounts caused overloading of the microwells, while smaller quantities did not yield sufficient polymer for further analysis. In subsequent experiments we used a fixed haematin concentration of 0.4 mol/well. Precipitation of haematin occurred rapidly after the addition of 0.8 mmol of acetic acid. After incubation at 37°C for 24 h, the plates were centrifuged and the supernatants collected for quantification of unreacted haematin (fraction I).
To verify the solubility and chemical characteristics of the precipitate, pellets were resuspended several times in DMSO or 2.5% SDS or 0.1 M sodium bicarbonate buffer (pH 9.1) to remove unreacted haematin from thehaematin polymer which is insoluble in those solvents. 9, 18 The yield of unpolymerized haematin was similar whether DMSO, SDS or bicarbonate buffer was used; DMSO was preferred because it has the advantage of being ready for use and it does not foam during microwell washing. Fraction II (DMSO-soluble) and the final pellet (fraction III, DMSO-insoluble) could be distinguished by infrared spectroscopy because fraction III, but not fraction II, gave distinctive peaks at 1662 and 1209 cm -1 already described for synthetic -haematin and native haemozoin. 9, 17 Those peaks characterize the iron-carboxylate bonds between adjacent haem molecules (Figure 1) .
In summary, haem polymerization in polystyrene microtitre wells from soluble haematin at acidic pH resulted in the formation of a stable polymer, insoluble in DMSO and with spectroscopic characteristics identical to synthetic and native haemozoin.
Quantification of haematin/ -haematin
The characteristic absorbance of haematin in 0.1 M NaOH at 405 nm (Soret band) was exploited to determine the relative amounts of haematin and -haematin in each fraction. Fractions I (unpolymerized haematin), II (DMSO-soluble) and III (final pellet, DMSO-insoluble) were serially diluted in 0.1 M NaOH and the amount of haematin in each fraction was calculated spectrophotometrically from a standard curve of the absorbance of haematin in 0.1 M NaOH at 405 nm; a separate standard curve was constructed for each experiment. The total amount of porphyrin recovered from all the fractions equalled the initial amount of haematin used. Table I shows the results from 12 different experiments, in triplicate, conducted at 37°C for 24 h from 0.4 mol/well of haematin. The yield of the reaction (52.7% 8.8% of the initial dose of haematin recovered as -haematin) was in line with published reports. 9 The results were highly reproducible: the variance was 1.3 10 -6 for fraction I, 0.003 for fraction II and 0.001 for fraction III.
The time course of -haematin formation was determined by stopping the reaction after 2, 4, 6, 8, 16 and 24 h and measuring the amount of porphyrin present in each fraction. After 2 h, c.10-15% of total porphyrin was found in fraction III. The amount of -haematin increased proportionally with time and after 16-24 h the reaction was complete. The progressive increase in porphyrin in fraction III was paralleled by a decrease in fraction II (Figure 2 ).
Screening of different compounds for HPIA
Using this microassay we then tested different compounds for their ability to interfere with haem polymerization. The experiments were conducted by mixing haematin with different equivalents of the antimalarial drugs, previously dissolved in the appropriate solvent, immediately before adding acetic acid. Precipitation and analysis of the different fractions were then conducted as described above.
When 50 L of an aqueous solution of chloroquine was mixed with haematin, a dose-dependent inhibition of -haematin formation was observed (Figure 3a ). An increasing concentration of chloroquine corresponded to increased amounts of porphyrin in fraction II and a decrease in fraction III; 50% inhibition of haem polymerization (IC 50 ) was obtained using 1.85 0.55 equivalents of chloroquine. The amount of unprecipitated haematin did not vary significantly. A similar pattern was found with amodiaquine and primaquine, with an IC 50 of 1.95 0.62 and 1.28 0.4 equivalents, respectively.
Other compounds, such as quinidine, artemisinin and dihydroartemisinin, were dissolved in ethanol. Ethanol did not interfere with haem polymerization and can therefore be used in this assay for water-insoluble compounds (the distinctive FT-IR peaks of -haematin were obtained in fraction III of ethanol-containing control wells). The IC 50 of quinidine was 4.65 1.2 equivalents. A dose-dependent inhibition of -haematin formation was obtained with artemisinin and its metabolite; unlike chloroquine, this was paralleled by an increase in the percentage of porphyrin present in fraction I (unprecipitated haematin) ( Figure 3b ).
Other drugs, including pyrimethamine and trimethoprim (inhibitors of the folate pathway) and atovaquone (an inhibitor of electron transport and pyrimidine biosynthesis), did not inhibit -haematin formation at any of the doses tested (Table II) .
The mechanism of action of the antimalarial compounds tested here, including their interaction with haem and its polymerization, is only partly understood. The latter is commonly ascribed to one or both of the following proposed mechanisms: -interaction between the drug and the haem electronic systems; -oxo bridge between haem ferric iron and hydroxyl groups of the drugs whenever present. 19 We have previously substantiated the -adduct hypothesis and the stabilizing role of oxo bridges by showing that non-iron porphyrins can effectively prevent haem polymerization. 17 These results also indicate that anti-malarial drugs whose mechanism of action is based on HPIA can be distinguished from unrelated compounds using the proposed microassay.
Of the drugs tested in the present study, the quinolinecontaining drugs chloroquine, amodiaquine, primaquine and quinidine fulfil one or both of these criteria: they all can interact with the haem system, and quinidine has in addition a hydroxyl group in the benzylic position which allows the formation of an oxo bridge with the central ferric iron of haem. However, a high quinidine:haem ratio seems to be necessary to obtain 50% inhibition of haem polymerization: this could be explained by the presence of the bulky quinuclidine side chain which may hinder interaction between the quinoline ring and haem. Moreover, although the chemical structure of primaquine supports HPIA activity, our data seem to contradict earlier experiments where it reportedly failed to inhibit haem polymerization; 10,20 nonetheless, the drug proved consistently active in our model. This suggests that the binding constants, which vary with the drug and with factors such as pH, temperature and medium, govern the reaction, and could also help to explain the variable results obtained using different experimental conditions. As for peroxidebridge antimalarials, their mode of action is still not completely resolved. Mössbauer data indicate that an oxo bridge is involved between the ferric iron haem and the opened endoperoxide group of the artemisinin. The binding of artemisinin to haem both potentiates the redox activity of haem and inhibits haem polymerization. 21 These data are consistent with the reproducible HPIA activity of artemisinin in our assay. None of the antimalarial drugs studied was able to interfere with haematin polymerization when added at 2, 4, 6 or 8 h after the reaction had started: this suggests that the antimalarial drugs tested can only interfere with the initial formation of haem oligomers when haem molecules are still in solution (Table III) . Under these experimental conditions addition of antimalarial compounds after the start of the reaction could not efficiently terminate chain extension.
In conclusion, this 96-well plate spectrophotometric -haematin inhibition assay proved reproducible for all drugs tested and was suited for both water-soluble and -insoluble compounds. The need for two centrifugations is rate-limiting and undoubtedly make this assay less well adapted to high throughput screening than methods using radiolabelled haematin. However, this micromethod may be more suited to medium-size screening, in that it is cheap and easy to perform, requires modest equipment and relatively little training, and avoids the logistical problems related to disposal of radioactive material. All steps can be completed in about 24 h if the assay is conducted as described, but the time could be reduced if only fraction III was quantified. Such modification would also allow for testing compounds with absorbance around Soret's band, which would otherwise interfere with fractions I and II.
This assay could be used for primary screening to select active compounds for further testing for inhibition of parasite growth on whole cell in-vitro culture systems using P. falciparum. Alternatively, the HPIA can be used to study the mechanism of action of compounds with known antimalarial activity. Larger series of compounds will be tested to validate and refine the assay further. 
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